Li Angela, Anbuchelvan Madhavan, Fathi Amir, Abu-Zahra Maya, Evseenko Denis, Petrigliano Frank A, Dar Ayelet
Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Department of Stem Cell Research and Regenerative Medicine, University of Southern California, Los Angeles, CA, United States.
Front Cell Dev Biol. 2023 Apr 18;11:1173794. doi: 10.3389/fcell.2023.1173794. eCollection 2023.
Chronic muscle injuries, such as massive rotator cuff tears, are associated with progressive muscle wasting, fibrotic scarring, and intramuscular fat accumulation. While progenitor cell subsets are usually studied in culture conditions that drive either myogenic, fibrogenic, or adipogenic differentiation, it is still unknown how combined myo-fibro-adipogenic signals, which are expected to occur , modulate progenitor differentiation. We therefore evaluated the differentiation potential of retrospectively generated subsets of primary human muscle mesenchymal progenitors in multiplexed conditions in the presence or absence of 423F drug, a modulator of gp130 signaling. We identified a novel CD90CD56 non-adipogenic progenitor subset that maintained a lack of adipogenic potential in single and multiplexed myo-fibro-adipogenic culture conditions. CD90CD56 demarcated fibro-adipogenic progenitors (FAP) and CD56CD90 progenitors were typified as myogenic. These human muscle subsets exhibited varying degrees of intrinsically regulated differentiation in single and mixed induction cultures. Modulation of gp130 signaling via 423F drug mediated muscle progenitor differentiation in a dose-, induction-, and cell subset-dependent manner and markedly decreased fibro-adipogenesis of CD90CD56 FAP. Conversely, 423F promoted myogenesis of CD56CD90 myogenic subset, indicated by increased myotube diameter and number of nuclei per myotube. 423F treatment eliminated FAP-derived mature adipocytes from mixed adipocytes-FAP cultures but did not modify the growth of non-differentiated FAP in these cultures. Collectively, these data demonstrate that capability of myogenic, fibrogenic, or adipogenic differentiation is largely dependent on the intrinsic features of cultured subsets, and that the degree of lineage differentiation varies when signals are multiplexed. Moreover, our tests performed in primary human muscle cultures reveal and confirm the potential triple-therapeutic effects of 423F drug which simultaneously attenuates degenerative fibrosis, fat accumulation and promotes myo-regeneration.
慢性肌肉损伤,如大面积肩袖撕裂,与进行性肌肉萎缩、纤维化瘢痕形成和肌内脂肪堆积有关。虽然祖细胞亚群通常在驱动肌源性、纤维生成性或脂肪生成性分化的培养条件下进行研究,但尚不清楚预期会出现的肌-纤维-脂肪生成联合信号如何调节祖细胞分化。因此,我们评估了在存在或不存在423F药物(一种gp130信号调节剂)的多重条件下,回顾性生成的原代人肌肉间充质祖细胞亚群的分化潜能。我们鉴定出一种新的CD90CD56非脂肪生成祖细胞亚群该亚群在单一和多重肌-纤维-脂肪生成培养条件下均保持缺乏脂肪生成潜能的特性。CD90CD56界定了纤维-脂肪生成祖细胞(FAP),而CD56CD90祖细胞则以肌源性为典型特征。这些人肌肉亚群在单一和混合诱导培养中表现出不同程度的内在调节分化。通过42F药物对gp130信号的调节以剂量、诱导和细胞亚群依赖的方式介导肌肉祖细胞分化,并显著降低CD90CD56 FAP的纤维-脂肪生成。相反,423F促进了CD56CD90肌源性亚群的肌生成,表现为肌管直径增加和每个肌管的核数量增加。423F处理从混合脂肪细胞-FAP培养物中消除了FAP衍生的成熟脂肪细胞,但未改变这些培养物中未分化FAP的生长。总体而言,这些数据表明,肌源性、纤维生成性或脂肪生成性分化的能力在很大程度上取决于培养亚群的内在特征,并且当信号多重化时,谱系分化的程度会有所不同。此外,我们在原代人肌肉培养中进行的测试揭示并证实了423F药物的潜在三重治疗效果,即同时减轻退行性纤维化、脂肪堆积并促进肌再生。